Results 171 to 180 of about 47,221 (287)

Early Detection of Acute and Early‐Onset Cancer Therapy‐Related Cardiac Dysfunction in Children With Cancer Using a Multiparametric Approach: Methodological Aspects of the EARLY Study

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Cancer therapy‐related cardiac dysfunction (CTRCD) is among the most important adverse effects of treatment of childhood cancer. In the EARLY study (Early detection of acute and early‐onset cARdiovascuLar toxicity in children with cancer using a multiparametric approach), cardiac function in children treated for cancer was monitored
Theodorus W. Kouwenberg, Heynric B. Grotenhuis, Leontien C. M. Kremer, Esmée C. de Baat, Auke Beishuizen, Max M. van Noesel, Livia Kapusta, Rutger A. J. Nievelstein, Birgitta K. Velthuis, Martijn G. Slieker, Tim Leiner, Bianca A. W. Hoeben, Annelies M. C. Mavinkurve‐Groothuis, Elizabeth A. M. Feijen   +13 more
wiley   +1 more source

Discovery of natural products that modulate signaling in patient-derived cells. [PDF]

RSC Chem Biol
Balsamo JA, Thirman HL, Penton KE, Froese JT, Reisman BJ, Lima SM, Grider-Hayes MJ, Potts CR, Irish JM, Brent Ferrell P, Bachmann BO.   +10 more
europepmc   +1 more source

Neoadjuvant chemotherapy for soft‐tissue sarcoma of the extremities: A post‐hoc Sarculator‐based risk analysis of the EORTC 62961–ESHO 95 randomized trial

Cancer, Volume 132, Issue 9, 1 May 2026.
Abstract Background In the EORTC 62961–ESHO 95 randomized trial (European Organization for Research and Treatment 62961–European Society of Hyperthermia Oncology 95; ClinicalTrials.gov identifier NCT00003052), neoadjuvant chemotherapy (NAC) combined with regional hyperthermia (RHT) improved survival in patients with soft tissue sarcoma (tumor size >5 ...
Markus Albertsmeier, Valeria Milani, Lars H. Lindner, Gabriele Tinè, Sandro Pasquali, Dario Callegaro, Alessandro Gronchi, Hans‐Roland Dürr, Alexander Klein, Dorit Di Gioia, Sultan Abdel‐Rahman, Michael Schmidt, Jens Werner, Michael von Bergwelt‐Baildon, Rosalba Miceli, Rolf Issels   +15 more
wiley   +1 more source

Cardiotoxicity associated with anticancer therapies for gynecological tumors. [PDF]

Front Cardiovasc Med
Yang L, Liao J, Li J, Wang Z.
europepmc   +1 more source

Targeting the nuclear export receptor exportin‐1 in acute myeloid leukaemia: From biology to clinical translation

Clinical and Translational Medicine, Volume 16, Issue 5, May 2026.
• XPO1 hyperactivation promotes leukaemogenesis by altering nucleocytoplasmic transport and transcriptional control in acute myeloid leukaemia (AML). • Selinexor and eltanexor show preferential activity in NPM1‐mutated, DEK::NUP214‐positive and SF3B1‐mutated myeloid neoplasms.
Yifan Liu, Xiaoya Yun, Weidong Ding, Suxiao Li, Hui Liu   +4 more
wiley   +1 more source

Remote ischemic conditioning for safe cardioprotection in cardio-oncology? [PDF]

Basic Res Cardiol
Totzeck M, Rassaf T.
europepmc   +1 more source

Dietary Ergothioneine as a Novel Anti‐Aging Nutraceutical: Mechanisms, Bioavailability, and Future Perspectives

Food Frontiers, Volume 7, Issue 3, May 2026.
ABSTRACT Ergothioneine (EGT), a natural thiol derivative, has gained attention as a geroprotective nutraceutical. Preclinical research shows EGT scavenges free radicals, maintains mitochondrial integrity, slows telomere erosion, and regulates proteostasis via autophagy and senescent cell clearance.
Tian‐Tian Tian, Liang Chen, Zhen‐Zhen Dong, Chao Yang   +3 more
wiley   +1 more source

Exploring the Pleiotropic Cardioprotective Effects of GLP-1 Receptor Agonists in Preventing Anthracycline-Induced Cardiotoxicity: A Theoretical Proposal for Future Research. [PDF]

Medicines (Basel)
Repp ML, Chinyere IR, Teran S, Bast J, Kondapalli L.   +4 more
europepmc   +1 more source

TNF/TNF-R1 pathway is involved in doxorubicin-induced acute sterile inflammation [PDF]

, 2013
Aaes, Tania Love, Bachert, Claus, Delvaeye, Tinneke, Heyndrickx, Liesbeth, Kaczmarek, Agnieszka, Krysko, Dmitri, Krysko, Olga, Leybaert, Luc, Vandenabeele, Peter   +8 more
core   +1 more source

Outcomes and salvage strategies for large B‐cell lymphoma progressing after second‐line CAR T‐cell therapy: A DESCAR‐T study from the LYSA group

HemaSphere, Volume 10, Issue 5, May 2026.
Abstract Relapse after chimeric antigen receptor (CAR) T‐cell therapy in large B‐cell lymphoma (LBCL) is associated with a dismal prognosis. Although Phase 3 trials have established CAR T‐cells as standard second‐line (2L) therapy, outcomes and optimal management after relapse in this setting remain unknown because no real‐world data are currently ...
Pierre Sesques, Guillaume Manson, Guillaume Cartron, François‐Xavier Gros, Franck Morschhauser, Cristina Castilla‐Llorente, Gabriel Brisou, Pierre Bories, Catherine Thieblemont, Laurianne Drieu La Rochelle, Benoit Tessoulin, Axel André, Cedric Rossi, Jérôme Paillassa, Stephanie Guidez, Antoine Capes, Laura Herbreteau, Sylvain Choquet, Jacques‐Olivier Bay, Adrien Chauchet, Laure Lebras, Fabien Claves, Julie Abraham, Jean‐Valère Malfuson, Marie‐Thérèse Rubio, Justine Decroocq, Luc‐Matthieu Fornecker, Gandhi Damaj, Ludovic Fouillet, Magalie Joris, Michael Loschi, Olivier Hermine, Hadia Hafirassou, Emelie Van Zele, Vivien Dupont, Steven Le Gouill, Roch Houot, Vincent Camus   +37 more
wiley   +1 more source